Threshold: WHO-CHOICE proxy 1x PDB Rp 75 million/QALY; 3x PDB Rp 225 million/QALY (not an official InaHTAC threshold).
Comparator choice is clinical- and policy-driven: clopidogrel + aspirin is the Fornas-listed, JKN-reimbursed default oral DAPT for ACS in Indonesia, so the policy-relevant question is the incremental value of switching to ticagrelor, mirroring NICE TA236.
Drug prices ADJUDICATED to Indonesian e-Katalog LKPP (BPJS procurement): generic ticagrelor 90 mg Rp 8,325/tablet (Hexpharm Jaya, Dexa Medica) and generic clopidogrel 75 mg Rp 715/tablet (six suppliers). The 12-month DAPT drug-cost differential is therefore ~Rp 5.8 million, far smaller than the originator-Brilinta gap and materially improving ticagrelor's relative value at scale.
Ticagrelor (Brilinta 90 mg, BPOM reg. DKI1635301117A1) is BPOM-registered and commercially available in Indonesia, with multiple generic products now on e-Katalog; the live policy question is reimbursement parity with clopidogrel under JKN/Fornas.
PNPK 2019 Tata Laksana Sindroma Koroner Akut (Kepmenkes HK.01.07/MENKES/675/2019) and PERKI guidelines position potent P2Y12 inhibitors (ticagrelor/prasugrel) as preferred over clopidogrel for many ACS patients, so reimbursed access lags guideline preference.
Budget impact is driven by the large incident ACS cohort initiating DAPT each year and by ticagrelor's negotiated e-Katalog price; reviewers should verify the current Fornas listing/restriction wording for ticagrelor and the latest e-Katalog tender prices before interpreting acquisition-cost scenarios.